IL-1 Beta Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IL-1 Beta Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>IL1B</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Interleukin-1 Beta</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P01584</td>
</tr>
<tr>
<td class="label">Length</td>
<td>269 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>30.7 kDa</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2q14.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3553</td>
</tr>
<tr>
<td class="label">Cellular Localization</td>
<td>Secreted (cytokine)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>IL-1 Family Cytokine</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">IL1R1</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">IL1RAcP</td>
<td>Coreceptor</td>
</tr>
<tr>
<td class="label">IL1RN</td>
<td>Decoy receptor</td>
</tr>
<tr>
<td class="label">CASP1</td>
<td>Protease</td>
</tr>
<tr>
<td class="label">MYD88</td>
<td>Adapter protein</td>
</tr>
<tr>
<td class="label">IRAK4</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>Inflammasome component</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">971 edges</a></td>
</tr>
</table>
Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that plays a central role in the innate immune response and neuroinflammation. As one of the most biologically active members of the IL-1 family, IL-1β is critical for mounting inflammatory responses but also contributes to chronic neuroinflammation in neurodegenerative diseases. In the brain, IL-1β is produced by [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes), and [neurons](/entities/neurons), where it regulates fever generation, pain perception, sleep patterns, and synaptic plasticity. The cytokine is strongly implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and traumatic brain injury.
Overview
IL-1β is synthesized as a 31 kDa pro-form (pro-IL-1β) that requires proteolytic cleavage to become biologically active. The mature 17 kDa form is secreted and binds to the IL-1 receptor type I (IL-1R1), which recruits the IL-1 receptor accessory protein (IL-1RAcP) to form a signaling-competent complex.
Structure
IL-1β adopts a unique β-barrel structure distinct from the helical cytokine fold seen in other interleukin families:
- β-trefoil fold: 12 β-strands forming a barrel-like structure
- Three-fold symmetry: Characteristic of IL-1 family proteins
- Receptor binding sites: Multiple sites for IL-1R1 and IL-1RAcP interaction
Structural Features
Propeptide cleavage site: Caspase-1 cleavage at Asp116-Ala117 generates mature cytokine
Receptor binding interfaces: Multiple regions contribute to high-affinity receptor engagement
Secretion signal: No classical signal peptide; secreted via unconventional pathwaysNormal Function
Immune System
IL-1β is a master regulator of inflammation:
- Fever generation: Acts on hypothalamus to induce prostaglandin synthesis
- Acute phase response: Stimulates hepatic acute phase protein production
- Leukocyte recruitment: Induces adhesion molecule expression on endothelium
- Pain mediation: Sensitizes nociceptors through prostaglandin production
- Sleep regulation: Promotes slow wave sleep
Nervous System
In the CNS, IL-1β has both physiological and pathological roles:
- Synaptic plasticity: Modulates [LTP](/mechanisms/long-term-potentiation) and memory formation (biphasic effects)
- Neuroprotection: At low levels, can promote neuronal survival
- Neurotoxicity: At high levels, contributes to excitotoxicity
- Glial activation: Induces astrocyte and microglial activation
- [Blood-brain barrier](/entities/blood-brain-barrier): Modulates BBB permeability
Signaling Pathways
[NF-κB](/entities/nf-kb) pathway: Primary signaling cascade leading to inflammatory gene expression
MAPK pathways: p38, JNK, and ERK regulate stress responses
Caspase-1: Processes pro-IL-1β to active formRole in Disease
Alzheimer's Disease
IL-1β is a key driver of neuroinflammation in AD:
- Elevated expression: Increased in AD brain, especially around amyloid plaques
- Plaque association: Microglial IL-1β localizes to amyloid deposits
- Amyloid processing: Promotes [amyloid-beta](/proteins/amyloid-beta) production through [BACE1](/entities/bace1) upregulation
- [Tau](/proteins/tau) pathology: Enhances tau phosphorylation and NFT formation
- Synaptic loss: Contributes to synaptic dysfunction and memory impairment
- Genetic links: IL1B polymorphisms associated with AD risk
Parkinson's Disease
In PD, IL-1β mediates dopaminergic neuron loss:
- Substantia nigra elevation: High IL-1β in PD brains
- Microglial activation: Sustains chronic neuroinflammation
- Dopaminergic toxicity: Directly promotes neuron death
- [Alpha-synuclein](/proteins/alpha-synuclein): Modulates aggregation and propagation
Amyotrophic Lateral Sclerosis
IL-1β contributes to motor neuron degeneration:
- CSF elevation: Detectable in ALS cerebrospinal fluid
- Motor [cortex](/brain-regions/cortex) expression: High in affected motor regions
- Glial-neuron signaling: Feed-forward inflammation loop
- Disease progression: Correlates with progression rate
Multiple Sclerosis
Central role in MS pathophysiology:
- Demyelination: Promotes oligodendrocyte precursor death
- BBB disruption: Increases blood-brain barrier permeability
- Lesion formation: Accumulates in active demyelinating lesions
- Relapse activity: Correlates with clinical relapses
Traumatic Brain Injury
- Secondary damage: Exacerbates post-traumatic neurodegeneration
- Inflammasome activation: Caspase-1 dependent injury progression
Therapeutic Targeting
IL-1β is a major drug target with multiple approaches:
Approved Therapies
IL-1 Receptor Antagonist
- Anakinra (Kineret): Recombinant IL-1Ra
- Rilonacept (Arcalyst): IL-1R-Fc fusion protein
Anti-IL-1β Antibodies
- Canakinumab (Ilaris): Neutralizes IL-1β
Investigational Approaches
- Blood-brain barrier penetration strategies: Focused ultrasound, Trojan horse approaches
- CNS-selective inhibitors: Small molecules designed for CNS activity
- Gene therapy: AAV-delivered IL-1Ra
Challenges
- Physiological functions: Blocking IL-1β can impair host defense
- BBB delivery: Most biologics don't reach CNS
- Biomarker-guided therapy: Identifying patients who would benefit
Biomarker Potential
IL-1β serves as both a fluid biomarker and therapeutic target:
- CSF IL-1β: Elevated in AD, PD, ALS, MS
- Blood-brain barrier dysfunction: Correlates with vascular dysfunction
- Treatment response: Can track anti-inflammatory therapy efficacy
Interaction Network
Key Publications
PMID: 28739464(https://pubmed.ncbi.nlm.nih.gov/28739464/) - IL-1β and neuroinflammation in neurodegenerative disease
PMID: 25997342(https://pubmed.ncbi.nlm.nih.gov/25997342/) - Neuroinflammation mechanisms in neurodegeneration
PMID: 26437361(https://pubmed.ncbi.nlm.nih.gov/26437361/) - Cytokines as therapeutic targets in neurodegeneration
PMID: 24668245(https://pubmed.ncbi.nlm.nih.gov/24668245/) - Inflammatory pathways in Alzheimer's disease
PMID: 26245252(https://pubmed.ncbi.nlm.nih.gov/26245252/) - TNF-alpha in brain disease and therapy
PMID: 28942321(https://pubmed.ncbi.nlm.nih.gov/28942321/) - IL-1β in Parkinson's disease models
PMID: 27091020(https://pubmed.ncbi.nlm.nih.gov/27091020/) - IL-6/STAT3 signaling in neuroinflammation
PMID: 24745512(https://pubmed.ncbi.nlm.nih.gov/24745512/) - IFN-γ in neurodegeneration
PMID: 25009184(https://pubmed.ncbi.nlm.nih.gov/25009184/) - IL-6 and neuroinflammation
PMID: 28424685(https://pubmed.ncbi.nlm.nih.gov/28424685/) - [NLRP3 inflammasome](/entities/nlrp3-inflammasome) in neurodegenerationPathway & Interaction Diagram
Interactive diagram showing IL1B key relationships in the SciDEX knowledge graph (15 connections shown).
Mermaid diagram (expand to render)
See Also
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
- [IL-1 Family Cytokines](/mechanisms/il-1-family-cytokines)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Microglia](/cell-types/microglia)
- [Astrocytes](/cell-types/astrocytes)
External Links
- [UniProt P01584](https://www.uniprot.org/uniprot/P01584)
- [NCBI Gene 3553](https://www.ncbi.nlm.nih.gov/gene/3553)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000125538-IL1B)
- [KEGG Pathway: IL-1 signaling](https://www.kegg.jp/kegg-bin/show_pathway?map04620)
Background
The study of Il 1 Beta Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Lyman M, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/25997342/)
[Smith JA, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/26437361/)
[Rai SN, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/28942321/)
[Rothaug M, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27091020/)
[Guo S, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/26245252/)
[Walsh JG, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/28424685/)
[Basu A, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/24745512/)
[Patterson SL, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/25009184/)
[Kim YS, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/28424685/)
[Serada S, et al, (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/28739464/)